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Cancer induces a hypercoagulable state, and patients with cancer who suffer a throm-
botic event have a worse prognosis than those who do not. Recurrent pathologic thrombi
in patients with cancer are clinically managed with anticoagulant medications; however,
anticoagulant prophylaxis is not routinely prescribed owing to a complex variety of patient
and diagnosis related factors. Early identiﬁcation of patients at risk for cancer-associated
thrombosis would allow for personalization of anticoagulant prophylaxis and likely reduce
morbidity and mortality for many cancers.The environment in which a thrombosis develops
in a patient with cancer is complex and unique from patients without cancer, which creates
therapeutic challenges but may also provide targets for the development of clinical assays
in this context. Circulating tumor cells (CTCs) may play a role in the association between
cancer and thrombosis. Cancer metastasis, the leading cause of cancer-related deaths, is
facilitated by the hematogenous spread of CTCs, and CTCs accompany metastatic disease
across all major types of carcinomas. The role of CTCs in the pathogenesis of thrombosis
has not been studied due to the previous difﬁculty in identifying these rare cells, but the
interaction between these circulating cells and the coagulation system is an area of study
that demands attention. The development of CTC detection platforms presents a new tool
by which to characterize the role for CTCs in cancer-related hypercoagulability. In addi-
tion, this area of study presents a new avenue for assessing the risk of cancer-associated
thrombosis and represents a potential tool for predicting which patients may beneﬁt from
anticoagulant prophylaxis. In this review, we will discuss the evidence in support of CTC
induced hypercoagulability, and highlight areaswhereCTC-detection platformsmay provide
prognostic insight into the risk of developing thrombosis for patients with cancer.
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INTRODUCTION
Cancer is a hypercoagulable state, and the association of
venous thrombosis with cancer has been observed for centuries
(Trousseau, 1865). Thrombosis is a signiﬁcant contributor to mor-
bidity and mortality in cancer patients. Patients with cancer who
suffer a thrombosis as a part of their disease endure worse out-
comes (Sorensen et al., 2000). Despite the well established link
between cancer and venous thrombosis, anticoagulation is not
routine care for these patients (Akl et al., 2011a,b). This is due
in part to the increased bleeding risk associated with anticoagu-
lation in a population where only a fraction of patients develop
symptomatic thrombosis, and the risks of anticoagulation therapy
in patients treated with systemic chemotherapy and with disease
and/or therapy related thrombocytopenia. No clinical marker has
been developed which is capable of predicting in which patients
the beneﬁt of anticoagulation outweighs the increased risk of
bleeding.
The underlying cause of thrombosis in cancer is multifactorial,
including but not limited to, personal and family history of throm-
bosis, pre-treatment ﬁbrinogen and platelet levels, immobility
and fatigue, the increased use of indwelling catheters, and the
administration of certain chemotherapeutics and other anti-
cancer therapies which increase thrombotic risk (Dimopoulos
and Eleutherakis-Papaiakovou, 2004; Elice et al., 2009). However,
thrombosis can also herald the diagnosis of cancer, preceding any
cancer-related symptoms or treatments. This, in itself, underlines
the role for cancer in disrupting the normal physiological bal-
ance of the hemostatic system. The incidence of thrombosis in
cancer is strongly tied to cancer subtype and origin, suggesting
that cancer cells directly contribute to the hypercoagulable state
associated with cancer (i.e., adenocarcinoma vs. carcinoma or
colon vs. breast; Baron et al., 1998; Sorensen et al., 1998; Rick-
les and Levine, 2001; Blom et al., 2004). A multifactorial model
to estimate risk of thrombosis in patients receiving chemotherapy
has been validated which includes the cancer site, factors such as
platelet and leukocyte count, and hemoglobin level or the use of
erythropoiesis-stimulating agents, and body mass index to stratify
patients by risk to develop thrombosis. However, the majority of
patients predicted to have the highest risk of developing throm-
bosis in this model do not subsequently suffer from thrombosis
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(Khorana et al., 2008). Therefore, efforts to identify patients with
cancer who will develop venous thrombosis need to achieve bet-
ter speciﬁcity by including additional factors, such as circulating
tumor cell (CTC) count, which may have a role in developing
cancer-related thrombosis.
CTC–BLOOD PROTEIN INTERACTIONS
Tissue factor (TF) is the physiological initiator of coagulation and
is essential for hemostasis. TF is a transmembrane glycoprotein
and requires phospholipids in order to be procoagulant (Nemer-
son, 1968). TF-expressing cells are not typically exposed to the
blood. Only upon injury, when the architecture of the blood ves-
sel is disrupted, does the blood gain exposure to extravascular
TF-expressing cells. Therefore, in hemostasis, the activation of
coagulation is essentially localized to sites of hemorrhage.
In the context of metastatic cancer, CTCs intravasate into
the vasculature in order to reach distant locations and establish
metastatic foci. CTCs accompany metastatic disease across all
major types of carcinomas (Allard et al., 2004). Tumors have been
shown to express TF in vivo, and TF expression has been shown
to correlate with metastatic potential (Zacharski et al., 1983, 1986;
Lee et al., 2011; Liu et al., 2011; Ma et al., 2011; Tian et al., 2011;
Xu et al., 2011; Gil-Bernabe et al., 2012). Therefore, the process of
hematogenous metastasis may present TF-expressing tumor cells
to blood in the absence of a blood vessel injury. Whether metasta-
sizing cancer cells are involved in the development of thrombosis
has not been established. In vitro, cancer cells added to blood
or plasma promote coagulation in a TF- and phosphatidylserine
(PS)-dependent manner, and the coagulation kinetics are strongly
dependent upon the number of cancer cells tested (Berny-Lang
et al., 2011; Tormoen et al., 2011; Yates et al., 2011; Welsh et al.,
2012). However, extrapolation of in vitro coagulation assays to
in vivo phenomenon is not straightforward. Cancer cell lines may
not reproduce CTC procoagulant phenotypes, and extrapolation
of in vitro coagulation kinetics to physiological scenarios is compli-
cated by dynamic physiological environments seen in vivo. Along
these lines, blood ﬂow is a strong determinant of procoagulant
activity (Gemmell et al., 1988), yet a metastasizing cancer cell has
dynamic temporal and spatial relationships with the blood which
are unique from TF-bearing cells exposed at the site of a blood ves-
sel injury. For instance, an intravasating or extravasating tumor
cell is stationary relative to the blood ﬂow, and thereby would
experience rapid changes in coagulation kinetics due to the blood
ﬂow-mediated transport of coagulation factors to the stationary
cell. In contrast, CTCs in the bloodstream experience very little
relative blood ﬂow, as these cells are transported by viscous forces
within the ﬂowing blood. The resulting coagulation kinetics for
CTCs is therefore reliant upon diffusion of coagulation factors
to/from the cell surface; thus the coagulation kinetics for CTCs is
diffusion-limited.
The extent to which spatial and temporal relationships affect
procoagulant activity of CTCs is a topic of recent investigation. In
this issue, Lee et al. (2011) model the generation and coalescence
of thrombin by procoagulant CTCs within the circulation and
predict local thrombin concentration gradients surrounding the
CTCs to have complex relationships with cell counts and distribu-
tions within the vasculature. This work suggests that procoagulant
CTC counts strongly determine local thrombin concentra-
tions, which would likely be prognostic for risk of developing
thrombosis.
Cell-mediated coagulation requires the binding of coagula-
tion factors from solution, followed by the assembly of enzyme
complexes on the cell surface. This assembly is facilitated by the
exposure of PS. The exposure of PS and subsequent assembly of
enzyme complexes on the cell surface may be rate-limiting for the
cell’s procoagulant activity. In vitro, the procoagulant activity of
several cancer cell lines has been shown to correlate with the extent
of PS exposure, more so than the relative expression of TF, sup-
porting the notion that facilitation of enzyme complex assembly
is the rate determining mechanism for cancer cell-mediated coag-
ulation (Barrowcliffe et al., 2002; Pickering et al., 2004). Further,
space limitations of the PS-regions can severely reduce coagulation
kinetics, indicating a role for quantiﬁcation of procoagulant sur-
face area to assess the procoagulant activity of a cell (Haynes et al.,
2012). This limitation suggests that the procoagulant phenotype
of CTCs may be dependent upon the physical parameters (size
and surface area) of CTCs. In this issue, Phillips et al. (2012a,b)
demonstrate methods to utilize light microscopy to quantify the
physical parameters of volume, mass, surface area, and density of
CTCs, providing a novel technique to assess CTC heterogeneity in
cancer-associated hypercoagulability.
Characterizing the role for procoagulant CTCs to initiate coag-
ulation requires a method to functionally probe the ability of CTC
to mediate coagulation. Surface expression of TF could be deter-
mined through immunoﬂuorescent labeling methods, but these
approaches do not capture the activity of TF. The ability of TF to
initiate coagulation is dependent upon the cell membrane envi-
ronment, speciﬁcally the exposure of PS, as well as an “active” or
“decrypted” form of TF in order to facilitate coagulation. In this
issue, Tormoen et al. (2012) describe an approach utilizing ﬂuores-
cently labeled coagulation factors to characterize the procoagulant
nature of CTCs. This approach has potential to functionally char-
acterize the ability of CTCs to bind coagulation factors, which is
crucial for their ability to facilitate coagulation. This functional
labeling lends itself to current CTC detection platforms (Krivacic
et al., 2004; Hsieh et al., 2006), providing a novel method with
whichCTCplatforms canprovide novel insight into cancer-related
thrombosis.
CTC–PLATELET INTERACTIONS
It has been shown that platelets, the primary mediators of
hemostasis, play a key a role in mediating hematogenous metas-
tasis (Gasic et al., 1968, 1973). In vitro, tumor cells bind platelets
under shear stress (McCarty et al., 2000, 2002) and cause platelet
aggregation, and this ability correlates with metastatic potential
in vivo (Karpatkin et al., 1988; Amirkhosravi et al., 2003; Palumbo
et al., 2005; Erpenbeck et al., 2010). The mechanisms by which
platelet interactions confer metastatic potential upon CTCs are
complex. Platelets can deter NK cell destruction of CTCs in the
blood (Karpatkin et al., 1988; Im et al., 2004; Kopp et al., 2009).
Releasates from activated platelets include growth factors such as
platelet-derived growth factor, vascular endothelial growth fac-
tor, and transforming growth factor beta, and may support tumor
growth and may promote the establishment of metastatic tumor
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sites (Kepner and Lipton, 1981; Assoian et al., 1983; Mohle et al.,
1997; Nierodzik and Karpatkin, 2006). Recently, a murine model
of superﬁcial venous thrombophlebitis, a speciﬁc clinical pre-
sentation of thrombosis that can be associated with mucinous
tumors, was shown to depend upon platelet activation (Shao et al.,
2011). However, the role for platelet–CTC interactions for venous
thrombosis has not been established in different cancer-related
contexts.
LEUKEMIA CELL–BLOOD PROTEIN INTERACTIONS
While the extreme rarity of CTCs in human solid tumors has pre-
vented their characterization, leukemias, which are composed of
circulating cancer cells, or “liquid tumors,” supply vast numbers
of cancer cells to the bloodstream, making their isolation straight-
forward. Thrombosis is commonly seen with speciﬁc leukemia
subtypes, and surface expression of TF has been identiﬁed on some
leukemic cells associated with coagulopathy (De Stefano et al.,
2005; Falanga et al., 2008; Liu et al., 2008; Falanga and Marchetti,
2009; Ku et al., 2009; Musil and Krc, 2010). However, converse to
solid tumors and certain leukemia subtypes, hemorrhage is more
common in most acute leukemias as compared to thrombosis
(Barbui et al., 1998; Barbui and Falanga, 2001; Falanga and Barbui,
2001; Falanga and Rickles, 2003). Suggested mechanisms by which
leukemias induce hemorrhage include bone marrow crowding
and suppression of platelet production leading to thrombocy-
topenia. Acute myelogenous leukemia French-American-British
subtype M3 or acute promyelocytic leukemia (APL), is known to
surface-express TF as well as Annexin II (Menell et al., 1999), and
is associated with the highest risk of thrombosis and bleeding
amongst all leukemia subtypes. TF activity has been demon-
strated from APL cells in vitro, suggesting that these cells are
procoagulant. However, rather than developing focal thromboses,
patients with APL present with a diffuse coagulopathy that con-
sumes the coagulation factors within the blood leaving the patient
unable to maintain hemostasis, resulting in a hemorrhagic phe-
notype. The surface expression of Annexin II has been shown
to correlate with incidence of hemorrhage, and an Annexin II-
mediated binding of tissue type plasminogen activator has been
demonstrated in vitro (Menell et al., 1999). Therefore, in certain
conditions, leukemia cells may initiate and propagate coagulation,
while simultaneously facilitating anticoagulation, with the net
coagulant effect resulting in consumption of coagulation factors
until the patient is severely deﬁcient and deposed toward clinically
severe hemorrhage.
SUMMARY
Metastasizing CTCs must survive the blood circulation, and the
role that blood protein and blood cell interactions with CTCs
plays in the progression of metastatic disease in human cancers
remains ill-deﬁned. The association between cancer and thrombo-
sis suggests that the circulation is not inert toward CTCs, however
the characterization of human CTC and blood interactions has
been hampered by the technical difﬁculty in isolating and ana-
lyzing these rare cells. The emergence of clinical CTC detection
platforms in recent years has opened the possibility to charac-
terize the role that CTCs play in metastatic disease. One of the
challenges facing researchers in this ﬁeld is how to functionally
characterize CTCs within the technical constraints that current
CTC detection platforms require. This special edition of Fron-
tiers in Oncology describes several methods with which CTCs
are biophysically characterized using light microscopy techniques
(see Phillips et al., 2012a,b). The development of CTC detection
platforms to probe procoagulant properties of these cells presents
new opportunities for investigators to understand the relation-
ship between CTCs and blood proteins and/or blood cells. This
theme is explored in Tormoen et al. (2012). Finally, understanding
the complex environment that CTCs within the blood circulation
traverse, and the effects that this environment has on the pro-
coagulant phenotype of CTCs is addressed in Lee et al. (2012).
The therapeutic targeting of CTCs may provide new insight into
metastatic disease, including methods to interrogate the proco-
agulant nature of CTCs and understand how these relationships
impact cancer progression and cancer-related morbidities and the
response to antithrombotic therapies.
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